Dr Ranjitha Rao
Associate Professor
Department of Pathology
CURRENT ACADEMIC ROLE & RESPONSIBILITIES
Associate Professor
SUBJECTS CURRENTLY TEACHING
| Subject | Semester / Year |
|---|---|
| Pathology | III, IV, V semester MBBS |
ACADEMIC QUALIFICATIONS
| Degree | Specialisation | Institute | Year of passing |
|---|---|---|---|
| MD | Pathology | Karnataka Institute of Medical Sciences, Hubli | 2014 |
| MBBS | Karnataka Institute of Medical Sciences, Hubli | 2010 |
Experience
| Institution / Organisation | Designation | Role | Tenure |
|---|---|---|---|
| Kasturba Medical College, Mangalore | Assistant Professor | Nov 2014 – till date |
AREAS OF INTEREST, EXPERTISE AND RESEARCH
Area of Interest
Histopathology with special interest in gynecologic pathology,breast pathology,cytopathology and transfusion medicine
Area of Expertise
Histopathology, cytopathology
Area of 亚洲通_亚洲通官网
Breast and gynecologic pathology
Professional Affiliations & Contributions
KCIAPM
1. Rao R, Deviprasad D, Jaipuria B, Saha D ,Manisha N, Rao K S (2018) Mantle Cell Lymphoma of the Palatine Tonsil: A Rare Case Report. Iran J Otorhinolaryngol. 2018 ;30(100):297-300
2. Rao R, Giriyan SS, Rangappa P K. Clinicopathological profile of papillary carcinoma of thyroid: A 10-year experience in a tertiary care institute in North Karnataka, India. Indian J Cancer 2017;54:514-8
3. Venkataramana CG, Pai RR, Rao R, Nirupama M,Lobo FD, Sahoo KK.Clinicopathological study of medullary carcinoma of thyroid: A single institute experience.Thyroid Res Pract 2018;15:38-41.
4. Govindarajan S, Adiga DS,Lobo F D, Rao R, Prasad K, Venkataramana CG Advanced Stage Lung Cancer: Persisting Challenges in the Era of Molecular Targeted Therapy-Our Experience.JCDR 2018;12 (5):14-17.
5. Venkataramana CG,Kini H, Saha D, Rai S, Adiga D S, Rao R,Philipose C S.Histomorphologic Spectrum in Hyaline Vascular Variant of Castleman Disease. JCDR 2017;11 (8): EC01-EC04.
1. A study of p63 expression in papillary lesions of the breast to evaluate its utility as a marker to distinguish benign from malignant lesions. 2. A study of Oct-4/POU5F1, a stem cell transcription factor expression in breast cancer and its impact on the prognosis . 3. Advanced Stage Lung Cancer: Persisting Challenges in the Era of Molecular Targeted Therapy-Our Experience.